[go: up one dir, main page]

RU94041950A - Использование соединений ряда 3-аролоксипропиламинов в лечении недержания - Google Patents

Использование соединений ряда 3-аролоксипропиламинов в лечении недержания

Info

Publication number
RU94041950A
RU94041950A RU94041950/14A RU94041950A RU94041950A RU 94041950 A RU94041950 A RU 94041950A RU 94041950/14 A RU94041950/14 A RU 94041950/14A RU 94041950 A RU94041950 A RU 94041950A RU 94041950 A RU94041950 A RU 94041950A
Authority
RU
Russia
Prior art keywords
arylhydroxypropylamine
order
compounds
enuresis
treatment
Prior art date
Application number
RU94041950/14A
Other languages
English (en)
Other versions
RU2152786C2 (ru
Inventor
Брюс Тор Карл
Us]
Original Assignee
Эли Лилли энд Компани (US)
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22566762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU94041950(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эли Лилли энд Компани (US), Эли Лилли Энд Компани filed Critical Эли Лилли энд Компани (US)
Publication of RU94041950A publication Critical patent/RU94041950A/ru
Application granted granted Critical
Publication of RU2152786C2 publication Critical patent/RU2152786C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • External Artificial Organs (AREA)

Abstract

Недержание мочи у людей лечат посредством применения венлафаксина или соединения, выбранного из ряда арилоксипропиламинов.

Claims (1)

  1. Недержание мочи у людей лечат посредством применения венлафаксина или соединения, выбранного из ряда арилоксипропиламинов.
RU94041950/14A 1993-11-24 1994-11-23 Средство для лечения недержания мочи RU2152786C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15812193A 1993-11-24 1993-11-24
US08/158,121 1993-11-24

Publications (2)

Publication Number Publication Date
RU94041950A true RU94041950A (ru) 1996-09-20
RU2152786C2 RU2152786C2 (ru) 2000-07-20

Family

ID=22566762

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94041950/14A RU2152786C2 (ru) 1993-11-24 1994-11-23 Средство для лечения недержания мочи

Country Status (27)

Country Link
US (1) US5744474A (ru)
EP (1) EP0654264B1 (ru)
JP (1) JP3681009B2 (ru)
KR (1) KR100347277B1 (ru)
CN (1) CN1099284C (ru)
AT (1) ATE201594T1 (ru)
AU (1) AU679269B2 (ru)
CA (1) CA2136120C (ru)
CY (2) CY2245B1 (ru)
CZ (1) CZ289069B6 (ru)
DE (2) DE122005000005I2 (ru)
DK (1) DK0654264T3 (ru)
ES (1) ES2157958T3 (ru)
GE (1) GEP20064000B (ru)
GR (1) GR3036446T3 (ru)
HU (1) HU218920B (ru)
IL (1) IL111705A (ru)
LU (1) LU91140I2 (ru)
NL (1) NL300174I2 (ru)
NO (2) NO313535B1 (ru)
PH (1) PH30741A (ru)
PT (1) PT654264E (ru)
RU (1) RU2152786C2 (ru)
SI (1) SI0654264T1 (ru)
TW (1) TW344661B (ru)
UA (1) UA32429C2 (ru)
ZA (1) ZA949190B (ru)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506270A (en) * 1995-01-30 1996-04-09 American Home Products Corporation Venlafaxine in the treatment of hypothalamic amenorrhea in non-depressed women
ATE239467T1 (de) * 1996-03-11 2003-05-15 Lilly Co Eli Methode zur behandlung oder verhütung von interstitieller blasenentzundung
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
US6274171B1 (en) 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
EP1331003B1 (en) * 1996-03-25 2015-08-26 Wyeth LLC Extended release formulation containing venlafaxine
US6150396A (en) * 1997-03-07 2000-11-21 Eli Lilly And Company Methods of treating or preventing interstitial cystitis
CA2337507A1 (en) * 1998-07-16 2000-01-27 Massachusetts Institute Of Technology Composition for treatment of stress
US6579899B1 (en) 1998-07-16 2003-06-17 Massachusetts Institute Of Technology Composition for treatment of stress
ATE487471T1 (de) * 1998-08-27 2010-11-15 Pfizer Health Ab Therapeutische formulierung zur verabreichung von tolterodin mit kontrollierter freisetzung
US6046242A (en) * 1998-11-27 2000-04-04 Basf Aktiengesellschaft Use of aryl-substituted cyclobutylalkylamines for treating urinary incontinence
US6342533B1 (en) 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
US6197828B1 (en) 1998-12-01 2001-03-06 Sepracor, Inc. Derivatives of (+)-venlafaxine and methods of preparing and using the same
ES2305606T3 (es) * 1999-04-06 2008-11-01 Sepracor Inc. Succinato de o-desmetilvenlafaxina.
ES2247572T3 (es) 1999-07-01 2006-03-01 PHARMACIA & UPJOHN COMPANY LLC (s,s)-reboxetina para tratar las cefaleas migrañosas.
US7291646B2 (en) 1999-11-24 2007-11-06 Wyeth Ethers of O-desmethyl venlafaxine
US6572890B2 (en) * 2000-01-13 2003-06-03 Osmotica Corp. Osmotic device containing venlafaxine and an anti-psychotic agent
DE10027290C2 (de) 2000-06-02 2002-07-11 Basf Coatings Ag Pulverklarlackdispersionen (Pulverslurry-Klarlacke) und ihre Verwendung
DE10059412A1 (de) * 2000-11-30 2002-06-13 Gruenenthal Gmbh Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie der Harninkontinenz
NZ539791A (en) 2001-02-12 2006-11-30 Wyeth Corp Novel succinate salt of o-desmethyl-venlafaxine
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
IL146462A (en) * 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
UA77234C2 (en) * 2001-12-05 2006-11-15 Wyeth Corp Monohydrate of venlafaxine hydrochloride and methods for its preparation (variants)
JP2005511736A (ja) * 2001-12-05 2005-04-28 ワイス 新規塩酸ベンラファクシンの結晶多形体およびその作成方法
GB0202265D0 (en) * 2002-01-31 2002-03-20 Arachnova Therapeutics Ltd New therapeutic use
WO2003082805A1 (en) * 2002-03-28 2003-10-09 Synthon B.V. Low water-soluble venlafaxine salts
MXPA04011529A (es) * 2002-04-24 2005-08-15 Cypress Bioscience Inc Prevencion y tratamiento de trastornos somaticos funcionales, incluyendo trastornos relacionados con la tension.
DE10224107A1 (de) * 2002-05-29 2003-12-11 Gruenenthal Gmbh Kombination ausgewählter Opioide mit anderen Wirkstoffen zur Therapie der Harninkontinenz
WO2004019892A2 (en) * 2002-08-30 2004-03-11 Watson Pharmaceuticals, Inc. Drug delivery system for treating urinary incontinence
GB0221438D0 (en) * 2002-09-16 2002-10-23 Avecia Ltd Processes and compounds
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
US20070077301A1 (en) * 2002-12-23 2007-04-05 Meyer Glenn A Venlafaxine osmotic device formulation
JP2006522144A (ja) * 2003-04-04 2006-09-28 ダイノゲン ファーマシューティカルズ，インコーポレイテッド 下部尿路障害の治療方法
CA2564994A1 (en) * 2004-04-30 2005-11-10 Warner-Lambert Company Llc Substituted morpholine compounds for the treatment of central nervous system disorders
WO2006022420A1 (ja) 2004-08-25 2006-03-02 Takeda Pharmaceutical Company Limited 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
WO2006071868A2 (en) * 2004-12-23 2006-07-06 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof
TW200639161A (en) 2005-03-14 2006-11-16 Teva Pharma Process for the purification of duloxetine hydrochloride
EP1838692A2 (en) 2005-09-22 2007-10-03 Teva Pharmaceutical Industries Ltd Dnt-maleate and methods of preparation thereof
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
DK1954669T3 (en) 2005-12-01 2015-10-12 Auspex Pharmaceuticals Inc SUBSTITUTED phenethylamines a serotonergic AND / OR NOREPINEPHRINERG ACTIVITY
WO2007067501A1 (en) 2005-12-05 2007-06-14 Wyeth Process for selective synthesis of enantiomers of substituted 1-(2-amino-1-phenyl-ethyl)-cyclohexanols
WO2007067581A1 (en) * 2005-12-05 2007-06-14 Teva Pharmaceutical Industries Ltd. 2-(n-methyl-propanamine)-3-(2-naphthol) thiophene, an impurity of duloxetine hydrochloride
EP1826204A1 (en) 2006-02-28 2007-08-29 Laboratorios Del Dr. Esteve, S.A. Process for obtaining enantiomers of duloxetine precursors
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
WO2008140859A1 (en) 2007-03-15 2008-11-20 Auspex Pharmaceuticals, Inc. Deuterated venlafaxines and 0-desmetylvenlafaxines with serotoninergic and / or norepinephrinergic activity
WO2020014336A1 (en) 2018-07-11 2020-01-16 Dignify Therapeutics, Llc Method of treating voiding dysfunction

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US4018895A (en) * 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
GR75395B (ru) * 1980-11-14 1984-07-13 Lilly Co Eli
IE56324B1 (en) * 1982-12-13 1991-06-19 American Home Prod Phenethylamine derivatives and intermediates therefor
US4761501A (en) * 1983-10-26 1988-08-02 American Home Products Corporation Substituted phenylacetamides
KR880007433A (ko) * 1986-12-22 1988-08-27 메리 앤 터커 3-아릴옥시-3-치환된 프로판아민
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
CA1329937C (en) * 1987-04-09 1994-05-31 Dennis Charles Thompson 1-phenyl-3-naphthalenyloxypropanamines
SE8804003D0 (sv) * 1988-11-04 1988-11-04 Pharmacia Ab Compounds for the treatment of urinary incontinence
US5236956A (en) * 1988-11-04 1993-08-17 Kabi Pharmacia Aktiebolag Compounds for the treatment of urinary incontinence
US5250571A (en) * 1988-11-14 1993-10-05 Eli Lilly And Company (S)-norfluoxetine in method of inhibiting serotonin uptake
DE3912232A1 (de) * 1989-04-11 1989-11-30 Klosa Josef Mittel gegen harninkontinenz
PH30083A (en) * 1991-02-25 1996-12-27 Lilly Co Eli Treatment of lower urinary tract disorders
EP0537915B1 (en) * 1991-09-27 1995-07-12 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-alkylthiophenoxy)propylamines as norepinephrine inhibitors
US5281624A (en) * 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
DK0617620T3 (da) * 1991-12-21 1999-06-07 Smithkline Beecham Plc Anvendelse af 5-HT4-modulatorer til fremstilling af et lægemiddel til behandling af blærelidelser
US5192751A (en) * 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence

Also Published As

Publication number Publication date
IL111705A0 (en) 1995-01-24
NO313535B1 (no) 2002-10-21
ZA949190B (en) 1996-05-20
CA2136120C (en) 2008-01-29
SI0654264T1 (en) 2001-10-31
ES2157958T3 (es) 2001-09-01
CN1107699A (zh) 1995-09-06
HUT72317A (en) 1996-04-29
DE69427337D1 (de) 2001-07-05
RU2152786C2 (ru) 2000-07-20
CY2245B1 (en) 2003-07-04
HK1013799A1 (en) 1999-09-10
CZ289394A3 (en) 1995-07-12
CY2005002I1 (el) 2010-07-28
KR100347277B1 (ko) 2003-03-06
DE122005000005I2 (de) 2006-06-08
GEP20064000B (en) 2006-12-11
ATE201594T1 (de) 2001-06-15
AU7896894A (en) 1995-06-01
NL300174I1 (nl) 2005-04-01
GR3036446T3 (en) 2001-11-30
EP0654264B1 (en) 2001-05-30
JPH07188003A (ja) 1995-07-25
CN1099284C (zh) 2003-01-22
PT654264E (pt) 2001-09-28
NO944456D0 (no) 1994-11-21
NO2005004I1 (no) 2005-02-10
NL300174I2 (nl) 2005-05-02
AU679269B2 (en) 1997-06-26
US5744474A (en) 1998-04-28
CZ289069B6 (cs) 2001-10-17
DE69427337T2 (de) 2001-10-31
LU91140I2 (fr) 2005-04-04
CA2136120A1 (en) 1995-05-25
NO944456L (no) 1995-05-26
HU9403369D0 (en) 1995-02-28
PH30741A (en) 1997-10-17
UA32429C2 (ru) 2000-12-15
HU218920B (hu) 2000-12-28
TW344661B (en) 1998-11-11
JP3681009B2 (ja) 2005-08-10
DK0654264T3 (da) 2001-07-30
DE122005000005I1 (de) 2005-05-12
KR950013511A (ko) 1995-06-15
EP0654264A1 (en) 1995-05-24
IL111705A (en) 2001-01-11
CY2005002I2 (el) 2010-07-28

Similar Documents

Publication Publication Date Title
RU94041950A (ru) Использование соединений ряда 3-аролоксипропиламинов в лечении недержания
RU94046294A (ru) Стероидные гликозиды для лечения гиперхолестеринэмии
RU94031102A (ru) Сульфамиды в качестве антагонистов эндотелина и способ лечения соответствующих заболеваний
DE122009000012I1 (de) Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen.
DE69831506D1 (en) 4-hydroxychinolin-3-carboxamide und hydrazide als antivirale wirkstoffe
PT772600E (pt) Compostos de imidazolilo substituido nas posicoes 1 e 2 para o tratamento da inflamacao
DE10075033I2 (de) substituierte Pyrazolyl-benzolsulfonamide zur Behandlung von Entzündungen.
RU94020410A (ru) Способ лечения или профилактики рвоты у млекопитающих и человека с использованием некоторых хинуклидиновых, пиперидиновых, азанорборнановых, этилендиаминовых производных и родственных им соединений
ATE143263T1 (de) Behandlung von neurodegenerativen erkrankungen
NO902800D0 (no) Fremgangsmaate for fremstilling av 11beta-aryl-4-oestrener.
WO1997003188A3 (de) Verwendung von mp52 oder mp121 zur behandlung und prävention von erkrankungen des nervensystems
IL119263A (en) Film for the treatment of soils by fumigation
CA2267309A1 (en) Use of 1-hydroxy-2-pyridones for the treatment of skin infections
DE69617005D1 (de) 2-amino-benzoxazinone zur behandlung von viralen infektionen
NO980793D0 (no) Anvendelse av aminoadamantanforbindelse som immunregulatorer
FI951511A0 (fi) IL-10:n käyttö insuliinista riippuvan diabetes mellituksen ennaltaestoon tai hoitoon
DE69420229D1 (de) Pharmazeutische Zusammensetzung zur Behandlung von AIDS
CA2082034A1 (en) Absorption of materials
ATE274904T1 (de) 4,5-dihydroxy-2-cyclopenten-1-on für die behandlung von diabetes mellitus
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
DE69419954D1 (de) Arzneimittel zur Behandlung von Hauterkrankungen
ATE274905T1 (de) 4,5-dihydroxy-2-cyclopentene-1-on für die behandlung von rheumatismus, entzündungen und autoimmunerkrankungen
DK0876144T3 (da) Terapeutiske anti-astmamidler indeholdende organiske selenforbindelser
RU94046312A (ru) Применение биологически активных уреидопроизводных для лечения индуцируемых лентивирусами заболеваний, продукты, содержащие уреидопроизводные
DE69737088D1 (de) Therapeutisches agens zur behandlung von fiv infektionen